LONDON (Thomson Financial) - ValiRx Plc. said it has entered into a licence
agreement with Cancer Research Technology Ltd. (CRT) to evaluate a novel
compound, VAL201, to arrest prostate cancer growth.
The cancer therapeutics company said it has the option to acquire exclusive
worldwide rights to the compound as an anti-cancer agent and subsequently
progress to clinical trials.
Early studies have thus far indicated that this lead drug candidate may also
stop tumour growth in patients who are unresponsive to current treatments, the
company added.
TFN.newsdesk@thomson.com
bsu/jfr
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|